Acadia Pharmaceuticals | ACAD - Assets


Acadia Pharmaceuticals reported $1.74B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Corcept Therapeutics USD 888.7M 73.82M Jun/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Moderna USD 10.96B 527M Jun/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Prothena USD 302.58M 47.32M Jun/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026